Health & Biotech
Cannabis: Roots nudges CEO aside to take bigger toke of pot market
Check up: Enthusiasm rather than news is moving health stocks
Health might be another overnight success in 2020
Health: New-look ServTech places bet on Italian VR dentistry, shares move
Weed Week: Cannabis munchies not a safe bake
Health: Genetic Tech shares soar on confirmation sales of new breast cancer test are set for Q1
MGC takes aim at medical cannabis affordability with new line of products
Cannabis: Cann-made marijuana resin could be on the market by March
Health: CannPal wins a global licence for CSIRO’s tech to treat inflammation in animals; shares spike 74pc
9 of the most interesting biotech bosses in the game: part 2
9 of the most interesting biotech bosses in the game today: part 1
Pick of the pods: Best of the Health Kick Podcast in 2019
Health: Invion may have found its break in Chinese dermatology
Health: PainChek reveals exactly how much its grown in 2019; and says there’s more to come next year
Dr Boreham’s Crucible: Avita in for a busy 2020 with big expansion ambitions
Health: Gut treatment progress gives Anatara a 24pc boost
Weed Week: Canadians sunk some serious cash into reefer this year
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
